Loading...
XSHE300158
Market cap589mUSD
Jan 10, Last price  
4.30CNY
1D
-8.12%
1Q
1.90%
Jan 2017
-56.08%
IPO
-53.79%
Name

Shanxi Zhendong Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
XSHE:300158 chart
P/E
—
P/S
1.19
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
-0.15%
Rev. gr., 5y
1.18%
Revenues
3.63b
-2.75%
315,260,058461,053,642528,692,888930,329,7291,281,376,8571,387,054,7871,658,490,0761,919,484,9982,262,093,0883,282,999,9753,731,602,6263,419,750,4054,398,753,6034,847,833,2145,093,776,3343,728,555,3413,626,016,132
Net income
0k
39,227,45659,385,85568,024,64992,088,772119,768,81991,476,89174,017,15641,958,24064,646,180203,063,920301,535,9420142,762,719262,026,7382,617,429,56400
CFO
-190m
L
128,645,10133,184,99142,276,52232,397,2640189,400,099073,228,987151,844,461045,086,167154,477,419186,353,367221,942,198284,449,19986,308,195-189,950,976
Dividend
May 09, 20222.7 CNY/sh
Earnings
May 16, 2025

Profile

Shanxi Zhendong Pharmaceutical Co.,Ltd, together with its subsidiaries, researches, develops, manufactures, and markets pharmaceutical products and Chinese medicines in China. It offers cancer drugs, cardiovascular drugs, infectious disease drugs, and respiratory drugs; antibiotics, antitumor drugs, vitamins, etc.; Chinese medicines; calcium preparations; and active pharmaceutical ingredients, as well as sells gastrointestinal drugs. The company offers its products in various dosage forms, such as large volume injections, small volume injections, powder injections, lyophilized powders, tablets, hard capsules, granules, dry suspensions, ointments, psychotropic substances, and other formulations Shanxi Zhendong Pharmaceutical Co.,Ltd is based in Changzhi, China.
URL
http://www.zdjt.com
IPO date
Jan 07, 2011
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
3,626,016
-2.75%
3,728,555
-26.80%
Cost of revenue
3,564,147
3,706,199
Unusual Expense (Income)
NOPBT
61,869
22,356
NOPBT Margin
1.71%
0.60%
Operating Taxes
10,177
51,718
Tax Rate
16.45%
231.34%
NOPAT
51,693
(29,362)
Net income
Dividends
(2,774,236)
Dividend yield
36.24%
Proceeds from repurchase of equity
(110,666)
(256,451)
BB yield
1.60%
3.35%
Debt
Debt current
98
20,793
Long-term debt
3,065
2,162
Deferred revenue
42,770
42,495
Other long-term liabilities
74,715
74,715
Net debt
(2,302,691)
(2,716,588)
Cash flow
Cash from operating activities
(189,951)
86,308
CAPEX
(116,215)
Cash from investing activities
472,839
2,392,050
Cash from financing activities
(144,570)
FCF
(295,183)
195,661
Balance
Cash
2,248,838
2,739,543
Long term investments
57,015
Excess cash
2,124,552
2,553,115
Stockholders' equity
967,904
1,507,533
Invested Capital
4,295,319
3,799,423
ROIC
1.28%
ROCE
1.18%
0.42%
EV
Common stock shares outstanding
1,027,666
1,027,495
Price
6.75
-9.40%
7.45
-9.04%
Market cap
6,936,747
-9.38%
7,654,835
-9.04%
EV
4,634,057
4,938,247
EBITDA
183,544
148,368
EV/EBITDA
25.25
33.28
Interest
1,207
13,779
Interest/NOPBT
1.95%
61.63%